期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米联合地塞米松治疗10例合并肾功能不全的初治多发性骨髓瘤患者疗效分析 被引量：5

原文传递
导出
摘要 肾功能不全是多发性骨髓瘤（MM）常见的合并症和首发症状。有研究显示，合并肾功能不全的MM患者的预后较差，早期死亡率高，中位生存期不足2年。我们回顾性分析了我院应用硼替佐米联合地塞米松治疗10例合并肾功能不全的初治MM患者的疗效和安全性。
作者 李剑 周道斌 焦力 段明辉 韩冰 张薇 赵永强 沈悌
机构地区 中国医学科学院、北京协和医学院北京协和医院血液内科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第7期487-488,共2页 Chinese Journal of Hematology
关键词 肾功能不全 多发性骨髓瘤 地塞米松治疗 疗效分析 硼替佐米 初治 早期死亡率 中位生存期
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献6

  • 1Eleutherakis-Papaiakovou V,Bamias A,Gika D,et al.Renal impairment in multiple myeloma:incidence,correlations,and prognostic dignificance.Leuk Lymphoma,2007,48:337-341.
  • 2Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT.European Group for Blood and Manrrow Transplant.Br J Haematol,1998,102:1115-1123.
  • 3Jagannath S,Barlogie B,Berenson JR,et al.Bortezomib in recurrent and/or refractory multiple myeloma.Initial clinical experience in patients with impared renal function.Cancer,2005,103:1195-1200.
  • 4Roussou M,Kastritis E,Migkou M,et al.Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.Leuk Lymphoma,2008,49:890-895.
  • 5Ludwig H,Drach J,Graf H,et al.Reversal of acute renal impairment by bortezomib-based chemotherapy in patients with multiple myeloma.Haematologica,2007,92:1411-1414.
  • 6San Miguel JF,Schlag R,Khuageva NK,et al.Bortezomib plus melphalan and prednisoue for initial treatment of multiple myeloma.N Engl J Med,2008,359:906-917.

同被引文献55

  • 1孙启鑫,孟凡义,扶云碧,李利.硼替佐米单用或联合三尖杉酯碱体外诱导HL-60细胞凋亡实验研究[J].中国实验血液学杂志,2007,15(2):233-236. 被引量：15
  • 2武永吉.多发性骨髓瘤[M]//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:232-235.
  • 3BLADE J,SAMSON D,REECE D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant[J].Br J Haematol,1998,102:1115-1123.
  • 4HAROUSSEAU J L,ATTAL M,LELEU X,et al.Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:results of an IFM phaseⅡstudy[J].Haematologic,2006,91:1498-1505.
  • 5JAGANNATH S,DURIE B G,WOLF J,et al.Bortezomib therapy alone and combination with dexamethasone for previously untreated symptomatic multiple myeloma[J].Br J Haematol,2005,129:776-783.
  • 6Jiang CC, Lucas K, Avery-Kiejda KA, et al. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res, 2008 ; 68 ( 16 ) : 6708 - 6717.
  • 7Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Ce11,2000 ; 103 ( 6 ) :839 - 842.
  • 8Seo YW, Shin JN, Ko KH, et al. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J Biol Chem,2003 ;278(48) : 482922 -48299.
  • 9Kim JY, Ahn HJ, Ryu JH, et al. BH3-Only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor lalpha. J Exp Med, 2004;199(1) :113 -124.
  • 10Sun Y, Leaman DW. Involvement of Noxa in cellular apoptofic responses to interferon, double-stranded RNA, and virus infection. J Biol Chem, 2005; 280(16) :15561 -15568.

引证文献5

二级引证文献12

中华血液学杂志
2009年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部